Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells

Tanja Mesti, Nadia Bouchemal, Claire Banissi, Mohamed N. Triba, Carole Marbeuf-Gueye, Maja Cemazar, Laurence Le Moyec, Antoine F. Carpentier, Philippe Savarin, Janja Ocvirk

1 Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France
2 CSPBAT, UMR 7244, CNRS, Université Paris 13, Sorbonne Paris Cité, Bobigny, France
3 Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
4 Unité de Biologie Intégrative des Adaptations à l’Exercice, Université d’Evry, Evry, France
5 Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service de Neurologie, Bobigny, France
6 Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia


Received 30 November 2017
Accepted 21 October 2018

Correspondence to: Assoc. Prof. Janja Ocvirk, M.D., Ph.D., Institute of Oncology Ljubljana, Zaloška 2, Ljubljana. Phone: +386 1 5879 220; Fax: +386 1 5879 305; E-mail: jocvirk@onko-i.si

Disclosure: No potential conflicts of interest were disclosed.

Background. Malignant gliomas are rapidly growing tumours that extensively invade the brain and have bad prognosis. Our study was performed to assess the metabolic effects of bevacizumab on the glioma cells carrying the IDH1 mutation, a mutation, associated with better prognosis and treatment outcome. Bevacizumab is known to inhibit tumour growth by neutralizing the biological activity of vascular endothelial growth factor (VEGF). However, the direct effects of bevacizumab on tumour cells metabolism remain poorly known.

Materials and methods. The immunoassay and MTT assay were used to assess the concentration of secreted VEGF and cell viability after bevacizumab exposure. Metabolomic studies on cells were performed using high resolution magic angle spinning spectroscopy (HRMAS).

Results. miDH1-U87 cells secreted VEGF (13 ng/mL). Regardless, bevacizumab had no cytotoxic effect, even after a 72h exposure and with doses as high as 1 mg/mL. Yet, HRMAS analysis showed a significant effect of bevacizumab (0.1 mg/mL) on the metabolic phenotype of miDH1-U87 cells with elevation of 2-hydroxyglutarate and changes in glutamine group metabolites (alanine, glutamate, glycine) and lipids (polyunsaturated fatty acids [PUFA], glycerophosphocholine, and phosphocholine).

Conclusions. In miDH1-U87 cells, changes in glutamine group metabolites and lipids were identified as metabolic markers of bevacizumab treatment. These data support the possibility of a functional tricarboxylic acid cycle that runs in reductive manner, as a probable mechanism of action of bevacizumab in IDH1 mutated gliomas and propose a new target pathway for effective treatment of malignant gliomas.

Key words: idh1 mutation, malignant glioma, bevacizumab, metabolic fingerprint

Introduction

Malignant gliomas are rapidly growing tumours that extensively invade the brain and critically depend upon angiogenesis. Malignant gliomas are known to secrete vascular endothelial growth factor (VEGF) to stimulate angiogenesis.1 The IDH1 (NADP+-dependent isocitrate dehydrogenase) mutation occurs in the vast majority of WHO grade II or III gliomas and secondary glioblastomas. The p.Arg132His mutation (substitution from arginine to histidine) of isocitrate dehydrogenase I
(IDH1-R132H) is not only a frequent alteration (> 70%) but is also a major prognostic marker in malignant gliomas. Patients with an IDH1 mutation have better treatment outcomes and better survival. A number of studies have analysed the role of IDH mutations in cancer. The main biochemical alteration associated with these mutations is the gain of a new enzymatic activity in which mutant IDH reduces α-ketoglutarate (α-KG, also called 2-oxoglutarate) to 2-hydroxyglutarate (2-HG). This is in contrast to wild-type IDH1, which catalyzes the NADP+-dependent oxidative decarboxylation of isocitrate into α-KG. As a result, mutant IDH1 leads to elevated levels of 2-HG in tumour cells.

The tumorigenic effects of elevated 2-HG may be related to widespread changes in histone and DNA methylation.

The use of metabolic profiling in conjunction with data mining tools allows the study of differences between normal and cancer cells and provides insights into the metabolic processes within cells and tumour tissues. NMR high resonance magic angle spinning (HRMAS) analysis is a very specific method with high potential for assessing subtle changes in the metabolic profiles of cells. Using HRMAS, we have already shown that the VEGF inhibitor bevacizumab, which is used in recurrent glioblastoma, does not significantly impact the metabolism of wild-type U87 cells. This was in contrast to the VEGFR2-selective inhibitor SU1498 which elicits a dramatic increase in lipids, polyunsaturated fatty acids (PUFAs) in particular, due to an apoptotic response that is accompanied by accumulation of lipid droplets prior to DNA fragmentation, as we documented.

To date, there has been no published study in the literature examining the direct metabolic effect of bevacizumab on mIDH1 cells. Therefore, we performed HRMAS analysis of the metabolic effect of bevacizumab (0.1 mg/mL) on a glioma U87 cell line that carries the IDH1-R132H mutation (mIDH1-U87) and we present our data. First, we assessed the drug’s effects on cell proliferation, cell morphology, and VEGF secretion. Afterwards, we investigated the metabolic impact of bevacizumab on tumour cells by HRMAS. We report that bevacizumab has a significant effect on the metabolic phenotype of mIDH1-U87 cells, causing elevation of 2-hydroxyglutarate and changes in levels of the glutamine group of metabolites (alanine, glutamate, glycine) and in lipid signal (PUFA, glycerophosphocholine [GPC], and phosphocholine [PC]). Studying these metabolites by magnetic resonance spectroscopy (MRS) in patient samples could provide an early surrogate marker of bevacizumab response in tumour cells and, thus, might have a significant impact on clinical practice. These data support the possibility of a functional tricarboxylic acid cycle that runs in reductive manner, as a probable mechanism of action of bevacizumab in IDH1 mutated gliomas. With this we give not only new data of bevacizumab mechanism of action, but also we propose a new target pathway for effective treatment of malignant gliomas.

**Materials and methods**

**Cell phenotype, VEGF secretion and sensitivity to drugs**

The mIDH1-U87 (U87 cell line stably transfected with IDH1-R132H with a lentiviral vector, and was kindly provided by Marc Sanson [Hôpital de la Salpêtrière, Paris, France]) was maintained in Eagle’s minimal essential medium (EMEM) with 10% foetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin (Lonza, Verviers, Belgium). bevacizumab (Roche, Paris, France) was diluted with culture medium to working concentrations before use. As a control, a stock solution containing the corresponding excipient was prepared with 60 mg/mL of trehalose dehydrate, 5.8 mg/mL sodium dihydrogen phosphate monohydrate, and 1.5 mg di-sodium hydrogen phosphate dihydrate (all from Sigma Aldrich, Saint-Quentin Fallavier, France). VEGF secretion was assessed with the Quantikine ELISA kit for human VEGF (R&D Systems, Abingdon, UK), following the manufacturer’s instructions. The cells proliferation was assessed as follows: The mIDH1-U87 cells were seeded into and allowed to attach overnight. Cells (seeded in 24-well plates; 30,000 cells/well) were treated for 72 h with bevacizumab (from 0.1 mg/mL to 1 mg/mL) in triplicate wells. Duplicate experiments were performed. Cell viability was then assessed with the MTT assay following the procedure of Mosmann. The percentage of surviving cells is expressed as the ratio of optical density of treated cells versus untreated cells.

**1H-NMR spectroscopy**

Subconfluent mIDH1-U87 cells (4 x 10⁶ cells/60 mm diameter cell culture dishes) were incubated for 24 h and then treated with bevacizumab (0.1 mg/mL) or trehalose (0.24 mg/mL) for 24 h. The cells (6 x 10⁶ cells/dish) were then harvested in 0.5 mL cold (4°C) phosphate-buffered saline (PBS) in deu-
Treated water (Eurisotop, Gif-Sur-Yvette, France) using a cell scraper and were washed twice. After centrifugation (3 min at 4°C, 300 g), 50 µl inserts were filled with 6 million cells (using one insert per dish). Inserts were snap-frozen until NMR experiments. Ten inserts from different culture flasks were done for each condition (hereafter referred to as technical replicates) according to standard procedures. Cultures grown independently (in separate flasks and at different dates) were performed for each condition (hereafter referred to as biological replicates). The metabolomic profiles of cells were investigated in vitro with HRMAS. Spectra were acquired at 500 MHz on a Bruker AVANCE III NMR spectrometer (Bruker, Wissembourg, France), with an HRMAS probe. All experiments were performed at 294 K. Rotation rate was 4 kHz. Water signal was suppressed by a presaturation sequence using low power irradiation at the frequency of water. To remove broad signals produced by proteins and compounds exhibiting slow reorientation, a CPMG pulse sequence was used. The scan number was 128, the repetition rate of the spectra was 5 s. For resonance assignment purposes, TOCSY and JRES were also acquired. Spectra were first processed using NMRPipe with an exponential function corresponding to 0.3 Hz line broadening prior to Fourier transforms. Spectra were phased, and a baseline correction was applied between -0.5 and 10.5 ppm. The spectra were divided into 11,000 regions of 0.001 ppm width called buckets. Solvent signal was excluded. Each bucket was integrated and scaled using probabilistic quotient normalization.

Statistical analyses and metabolite identification in HRMAS spectra

Data for physiological processes are shown as mean values of at least two different experiments and expressed as means ± S.D. The data were first tested for normality of distribution and the differences between the experimental groups were evaluated by Student’s t-test for one-way analysis of variance. A p value of less than 0.05 (p < 0.05) was considered to be statistically significant. SigmaPlot statistical software was used.

Principal component analysis (PCA) was conducted to detect any outliers based on NMR signal variability, defined as observations situated outside the 95% confidence region of the model. Orthogonal projection to latent structure (OPLS) analysis was performed when no significant differences were observed with the PCA analysis. A leave-one-out internal cross-validation procedure was used to calculate the predictability of the model. The ability of the model to describe data and to correctly predict new data is expressed by the values of the parameters R2 and Q2. R2=1 indicates a perfect description of the data while Q2 = 1 indicates a perfect prediction of new data. Results are visualized by the scores and loadings plots. The scores plot shows the separation between groups. Scores are represented as a projection of the different samples on the predictive (Tpred) and the orthogonal (Torth) component. The loadings plot shows the distribution of the corresponding variables responsible for the separation observed in the scores plot. PCA and OPLS were conducted using SIMCA-P12 (Umetrics) and in-house Matlab (Mathworks) code based on the Trygg and Wold method. For metabolites considered as discriminant by the multivariate analysis, concentrations of metabolites were calculated by integration of their NMR signal.

Results

VEGF secretion was found (13 ng/mL) in the culture medium after 24 h incubation of mIDH1-U87 cells (Figure 1A). Bevacizumab, even in concentrations up to 1 mg/mL, and regardless of the exposure time, had no effect on mIDH1-U87 cell line viability (Figure 1B).
scribed for assessment of the metabolic fingerprint of bevacizumab on U87 cells, using trehalose-treated mIDH1-U87 cells as a control. The model was first calculated using a test set composed of 2 different culture sets (biological replicates) of trehalose-treated cells (each composed of 10 culture flasks), and 2 different cultures of bevacizumab-treated cells (each composed of 10 culture flasks). The corresponding score plot is presented in Figure 2. An OPLS model was calculated to characterize the metabolomic effect of bevacizumab on mIDH1-U87 cells (Figure 2A). The predictive ability of the model $Q^2$ was 0.93. To test the predictive ability of the model, a validation set was used. A projection of new samples (new trehalose-treated culture sets versus new bevacizumab-treated culture cells) was done using the model calculated with the test set. The score plot for the validation set is shown in Figure 2B. The AUROC obtained for the validation set was 0.82, which corresponds to good sensitivity and specificity of the prediction. The corresponding loadings coefficients plot is shown in Figure 2C. Using 2D experiments, Chenomx and HMDB database, the main metabolites, modified by bevacizumab treatment, were identified as (Figure 2D and Table 1), choline metabolite, GPC, in the area 3.65-3.71 ppm, with an increase of 35%, taurine (3.3-3.42 ppm) with an increase of 30%, alanine (1.475 ppm), glutamate (2.11/2.34/2.55/3.02 ppm) with an increase of 25%, creatine in the area 2.95 ppm and 3.02 ppm with an increase of 15% and 25%, respectively, and 2-HG (1.84/2.24/3 ppm) with an increase of 20%. Also, there were significant metabolite changes in the 3.2 ppm area identified as phosphocholine with an increase of 7%, in the same area where the GPC/choline ratio was also increased by 9%. Glycine was detected as increased in the 3.6 ppm area, but as NMR peaks were superimposed, the quantification of this metabolite was not possible.

![Figure 2. (A) Orthogonal projection to latent structure (OPLS)-DA score plot to discriminate metabolic effects of trehalose (blue) and bevacizumab (red) on mIDH1-U87 cells. (B) Projection of the spectra corresponding to the validation set. (C) OPLS loadings plot for mIDH1-U87 metabolic changes (significant changes marked with colours other than dark blue) after bevacizumab treatment. (D) $^1$H CPMG spectrum of cells incubated with bevacizumab (D, RED).](image)
TABLE 1. Principal discriminant metabolites. An up arrow (↑) corresponds to an increase of the concentration induced by bevacizumab

<table>
<thead>
<tr>
<th>Peak number</th>
<th>Chemical shift (ppm)</th>
<th>Attributions</th>
<th>Concentration variations Induced by Bev</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>184/2.24/3</td>
<td>2OH-glutarate</td>
<td>↑ 20%</td>
</tr>
<tr>
<td>2</td>
<td>3.22</td>
<td>GPC/chol</td>
<td>↑ 9%</td>
</tr>
<tr>
<td>3</td>
<td>2.11/3.24/3.55/3.02</td>
<td>glutamate</td>
<td>↑ 25%</td>
</tr>
<tr>
<td>4</td>
<td>1.475</td>
<td>alanine</td>
<td>↑ 25%</td>
</tr>
<tr>
<td>5</td>
<td>0.88</td>
<td>(CH2)n-CH3</td>
<td>↓ 32%</td>
</tr>
<tr>
<td>6</td>
<td>1.28</td>
<td>(CH2)n-CH2-(CH2)m</td>
<td>↓ 20%</td>
</tr>
<tr>
<td>7</td>
<td>2.95</td>
<td>creatine</td>
<td>↑ 15%</td>
</tr>
<tr>
<td>8</td>
<td>3.02</td>
<td>creatine</td>
<td>↑ 25%</td>
</tr>
<tr>
<td>9</td>
<td>3.2</td>
<td>Pcholine</td>
<td>↑ 7%</td>
</tr>
<tr>
<td>10</td>
<td>3.3-3.42</td>
<td>Taurine</td>
<td>↑ 30%</td>
</tr>
<tr>
<td>11</td>
<td>3.6</td>
<td>glycine</td>
<td>ND</td>
</tr>
<tr>
<td>12</td>
<td>3.65-3.71</td>
<td>GPC</td>
<td>↑ 35%</td>
</tr>
</tbody>
</table>

Bev = bevacizumab; GPC = glycerophosphocholine; ND = not determined; Pcholine = phosphocholine

**Discussion**

Using sensitive method as HRMAS analysis for the first time, we report, that Bevacizumab has a significant effect on metabolic phenotype of mIDH-U87 cells. It is presented with elevation of 2 hydroxyglutarate and changes in the group of glutamine metabolites (alanine, glutamate, glycine) and lipid signal (PUFA, glycerophosphocholine and phosphocholine). The HRMAS experiments were performed after 24 h exposure to bevacizumab, at a time point when no toxicity was observed by the MTT reduction assay, emphasizing the sensitivity of the HRMAS for detection of early drug-induced alterations of cancer cells.

Using HRMAS, we already showed that VEGF inhibitor, Bevacizumab does not significantly impact the metabolism of wild-type U87 cells, contrary to VEGFR2 selective inhibitor SU1498, with dramatic increase in lipids, and in particular in polyunsaturated fatty acids (PUFAs), due to an apoptotic response with accumulation of lipid droplets prior to DNA fragmentation, as we documented.12

The main biochemical alteration associated with the IDH-1 mutation is the gain of a new enzymatic activity which decreases α-ketoglutarate (α-KG) concentrations and increases 2-hydroxyglutarate (2-HG) concentrations. This is in contrast to wild-type IDH1, which catalyses the NADP+-dependent oxidative decarboxylation of isocitrate into α-KG. As a result, mutant IDH1 leads to elevated levels of 2-HG in tumour cells.5 The exact mechanism through which mutant IDH1 and 2-HG induce oncogenesis continues to be investigated, but recent studies confirm the hypothesis that 2-HG can competitively inhibit α-KG–dependent enzymes, which normally act to transfer amine groups from free amino acids to α-KG, as a first step in amino acid breakdown for oxidation in the tricarboxylic acid (TCA) cycle.6 TCA down-regulation has been associated with a selective advantage for cancer cells. Nutrients are converted to building blocks, such as amino acids and lipids, which are used for proliferation rather than being oxidized in the TCA cycle.16

According to our research data and using 2D experiments and the HMDB (Human Metabolome Database), the main metabolites modified by bevacizumab treatment were identified as GPC with a concentration increase of 35% in the area 3.65-3.71 ppm, taurine (3.3–3.42 ppm) with an increase of 30%, and there were significant metabolite changes in the 3.2 ppm area identified as PC with an increase of 7%, and in the GPC/choline ratio with an increase of 9%. GPC and PC have well-documented roles in membrane phospholipid breakdown.17 Ex vivo MRS studies of brain tumours have identified several biomarkers of tumour growth and apoptosis, among which are increased levels of choline-containing compounds, possibly due to cell membrane disruption and altered phospholipid metabolism.18 PC and GPC accumulation reflect early stages of growth arrest or apoptosis.19 The analysis of cisplatin-mediated apoptosis on ovarian cancer cells, showed enhanced apoptosis that was measured by increased PC and GPC concentrations.20 Elevated fatty acids and choline metabolism may be a sign of inhibited cell growth or apoptosis. In a study on human breast cancer cells, the increase in lipids (detected at 5.35, 1.3, and 0.9 ppm by NMR) during cytotoxic drug treatment was associated with mitochondrial damage, lipid droplet development, and formation of autophagic vacuoles.21 In malignant cells and tumours, appearance of a lipid peak at 1.3 ppm from CH2CH2CH2 has commonly been associated with ongoing cell death processes.22-24 In glioma cells, it has been demonstrated that PUFAs accumulate in BT4C glioma during gene therapy-induced programmed cell death (PCD), with pattern recognition identifying significant lipid changes 8-fold higher than normal in the area of 5.3 ppm and 2.8 ppm, corresponding to CH=CH and CH=CHCH=CH=CH, and 2 fold higher than normal in the area of 0.9 ppm and 1.3 ppm, corresponding to CH2-CH3 and CH2-CH2-CH2 as...
the most significant for monitoring the dynamics of PCD. On the other hand, an HRMAS study on glioma biopsies has shown that the taurine signal may be a robust apoptotic biomarker that is independent of tumour necrotic status. Namely, this study showed that taurine significantly correlated with apoptosis in both non-necrotic (R = 0.727, p = 0.003) and necrotic (R = 0.626, p = 0.0005) biopsies, but the PUFA changes in the 2.8 ppm area, observed in other studies as a marker of apoptosis, correlated only in non-necrotic biopsies (R = 0.705, p < 0.005). This is in agreement with our data, as we identified significant changes in the lipid area (0.88 ppm and 1.28 ppm), with (CH$_2$)$_n$-CH$_3$ and (CH$_2$)$_n$-CH$_3$-CH$_m$ signals, defined as PUFAs, being impacted with decreases of 32% and 20%, respectively, and an increase of 30% of taurine (3.3 - 3.42 ppm). This data also suggests that taurine may be a better biomarker of apoptosis in glial tumours than the change in PUFAs, which obviously differs according to the type of the tumour and correlates better with non-necrotic cancer types. Clearly it also correlates with the treatment used, as we had published the HRMAS analysis data of apoptotic impact of elevated PUFA by SU1498 treatment on U87 cells. The action of creatine has been shown to be linked with energy metabolism (formation of creatine phosphate) and inhibition of excitotoxicity. Decreased creatine has already been reported as a marker for highly proliferative cells and is found in gliomas. In that manner, creatine is used as carbon source. In that manner, glutamine provides a strong anaplerotic input to the TCA cycle via reductive flux from α-KG to citrate. IDH1-R132H expression results in elevated flux from glutamine to 2-HG through glutamate and α-KG. Thus, glutamate may become depleted, as it is converted first to α-KG and then to 2-HG. Except for the elevation of numerous free amino acids, IDH1-R132H cells show depletion of TCA cycle intermediates and elevation of lipid precursors such as GPC with a decrease of phosphatidylcholine.

The TCA cycle typically runs in the oxidative direction, but in our case, as other studies have shown, that in mammalian cells including glioblastoma cells, a reverse (reductive) flux between citrate and α-ketoglutarate can also exist when glutamine is used as carbon source. In that manner, glutamine contributes to production of alanine, which is usually the product of glycolysis and fatty acid synthesis. In the process, free ammonia is generated that can induce autophagy.

Conclusions

Our study was performed to assess the metabolic effects of Bevacizumab on the glioma cells carrying the IDH1 mutation, and for the first time we present data of the direct effects of bevacizumab on tumour cells metabolism. We observed dramatic changes in the metabolic phenotype of mIDH1-U87 cells after only 24h exposure to Bevacizumab using HRMAS Proton Magnetic Resonance Spectroscopy Analysis. We detected elevation of 2-HG levels and changes in the area of glutaminolysis metabolites and lipids (PUFA, GPC, and PC) as early markers of the metabolic effect of bevacizumab on mIDH1-U87 cells. These data support the possibility of a functional TCA cycle that runs in reductive direction inducing autophagy, as a probable mechanism of action of bevacizumab in IDH1-mutated glioma. Studying these metabolites by Magnetic Resonance
Spectroscopy (MRS) in patient samples could provide an early surrogate marker of bevacizumab response in tumour cells and, thus, might have a significant impact on clinical practice.

With this we give not only new data of Bevacizumab mechanism of action, but also we propose a new target pathway for effective treatment of malignant gliomas.

**References**


